高敏心肌肌钙蛋白、他汀治疗与冠心病风险
在 WOSCOPS 试验中,3,318 名无心肌梗死病史、低密度脂蛋白胆固醇升高的男性被随机分配至普伐他汀 40 mg 每日一次组或安慰剂组治疗 5 年。基线高敏肌钙蛋白 I 是心肌梗死或冠心病死亡的独立预测因素(最高四分位 ≥5.2 ng/l vs 最低四分位 ≤3.1 ng/l,HR 2.3,95%CI 1.4–3.7,p<0.001)。普伐他汀使肌钙蛋白浓度降低 13%(10%–15%,安慰剂校正后 p<0.001),1 年时肌钙蛋白变化与未来冠心病风险相关,且独立于降胆固醇作用。
要点
- 基线高敏肌钙蛋白 I 可独立预测心肌梗死或冠心病死亡,最高 vs 最低四分位 HR 2.3(95%CI 1.4–3.7)。
- 普伐他汀 40 mg 每日一次治疗使肌钙蛋白浓度降低 13%(10%–15%,安慰剂校正后 p<0.001)。
- 1 年时肌钙蛋白下降超过四分之一者未来冠心病风险最低(5 年 1.4%)。
核心结论
- 肌钙蛋白浓度可预测冠心病事件,他汀治疗可降低肌钙蛋白浓度,1 年时的变化与未来冠心病风险相关且独立于降胆固醇作用。
- 系列肌钙蛋白测定在评估心血管风险和监测治疗干预效果方面具有重要潜力。
研究设计与样本
- WOSCOPS(West of Scotland Coronary Prevention Study)随机对照试验,将低密度脂蛋白胆固醇升高且无心肌梗死病史的男性随机分配至普伐他汀 40 mg 每日一次组或安慰剂组治疗 5 年。
- 在 3,318 名参与者中,于基线和 1 年时使用高敏检测法测量血浆心肌肌钙蛋白 I 浓度。
主要发现
- 基线肌钙蛋白是心肌梗死或冠心病死亡的独立预测因素,最高四分位(≥5.2 ng/l)vs 最低四分位(≤3.1 ng/l)的 HR 为 2.3(95%CI 1.4–3.7,p<0.001)。
- 肌钙蛋白下降超过四分之一 vs 上升超过四分之一时,安慰剂组冠心病事件 HR 为 0.29(95%CI 0.12–0.72)vs 1.95(95%CI 1.09–3.49),趋势 p<0.001。
- 肌钙蛋白下降超过四分之一 vs 上升超过四分之一时,普伐他汀组冠心病事件 HR 为 0.23(95%CI 0.10–0.53)vs 1.08(95%CI 0.53–2.21),趋势 p<0.001。
- 普伐他汀使肌钙蛋白浓度降低 13%(10%–15%,安慰剂校正后 p<0.001),并使肌钙蛋白下降超过四分之一的人数翻倍(p<0.001),这些人的未来冠心病事件风险最低(5 年 1.4%)。
关键数值与推荐
- 基线肌钙蛋白最高四分位为 ≥5.2 ng/l,最低四分位为 ≤3.1 ng/l。
- 肌钙蛋白下降超过四分之一 vs 上升超过四分之一时,安慰剂组冠心病事件 HR 0.29(95%CI 0.12–0.72)vs HR 1.95(95%CI 1.09–3.49),趋势 p<0.001。
- 肌钙蛋白下降超过四分之一 vs 上升超过四分之一时,普伐他汀组冠心病事件 HR 0.23(95%CI 0.10–0.53)vs HR 1.08(95%CI 0.53–2.21),趋势 p<0.001。
- 普伐他汀组肌钙蛋白降低 13%(10%–15%,安慰剂校正后 p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac troponin is an independent predictor of cardiovascular mortality in individuals without symptoms or signs of cardiovascular disease. The mechanisms for this association are uncertain, and a role for troponin testing in the prevention of coronary heart disease has yet to be established. OBJECTIVES: This study sought to determine whether troponin concentration could predict coronary events, be modified by statins, and reflect response to therapy in a primary prevention population. METHODS: WOSCOPS (West of Scotland Coronary Prevention Study) randomized men with raised low-density lipoprotein cholesterol and no history of myocardial infarction to pravastatin 40 mg once daily or placebo for 5 years. Plasma cardiac troponin I concentration was measured with a high-sensitivity assay at baseline and at 1 year in 3,318 participants. RESULTS: Baseline troponin was an independent predictor of myocardial infarction or death from coronary heart disease (hazard ratio [HR]: 2.3; 95% confidence interval [CI]: 1.4 to 3.7) for the highest (≥5.2 ng/l) versus lowest (≤3.1 ng/l) quarter of troponin (p < 0.001). There was a 5-fold greater reduction in coronary events when troponin concentrations decreased by more than a quarter, rather than increased by more than a quarter, for both placebo (HR: 0.29; 95% CI: 0.12 to 0.72 vs. HR: 1.95; 95% CI: 1.09 to 3.49; p < 0.001 for trend) and pravastatin (HR: 0.23; 95% CI: 0.10 to 0.53 vs. HR: 1.08; 95% CI: 0.53 to 2.21; p < 0.001 for trend). Pravastatin reduced troponin concentration by 13% (10% to 15%; placebo adjusted, p < 0.001) and doubled the number of men whose troponin fell more than a quarter (p < 0.001), which identified them as having the lowest risk for future coronary events (1.4% over 5 years). CONCLUSIONS: Troponin concentration predicts coronary events, is reduced by statin therapy, and change at 1 year is associated with future coronary risk independent of cholesterol lowering. Serial troponin measurements have major potential to assess cardiovascular risk and monitor the impact of therapeutic interventions.
引用
- Ford I, Shah AS, Zhang R, et al. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. J Am Coll Cardiol. 2016. PMID: 28007133. doi:10.1016/j.jacc.2016.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。